Journal of Clinical and Experimental Toxicology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-1518-081136

Commentary - Journal of Clinical and Experimental Toxicology (2023) Volume 7, Issue 3

Novel approaches in clinical & experimental toxicology: Unraveling mechanisms of toxicity.

Coline Zhang*

Department of Clinical, International University of Japan, Minamiuonuma, Japan

*Corresponding Author:
Coline Zhang
Department of Clinical
International University of Japan
Minamiuonuma, Japan

Received: 05-June-2023, Manuscript No. AACETY-23-101367; Editor assigned: 06-June-2023, PreQC No. AACETY-23-101367 (PQ); Reviewed: 19-June-2023, QC No.AACETY-23-101367; Revised: 21-June-2023, Manuscript No. AACETY-23-101367 (R); Published: 28-June-2023, DOI: 10.35841/aacety-7.3.146

Citation: Zhang C. Novel approaches in clinical & experimental toxicology: Unraveling mechanisms of toxicity. J Clin Exp Tox. 2023 ;7(3):146

Visit for more related articles at Journal of Clinical and Experimental Toxicology


One of the key advancements in toxicology is the integration of high-throughput screening (HTS) techniques. HTS allows for the rapid screening of thousands of chemicals against specific cellular targets, providing valuable information on their potential toxic effects. By combining HTS with computational modeling, toxicologists can predict the toxicological properties of chemicals based on their structural features and target interactions, reducing the need for extensive animal testing [1].

Another promising approach is the use of organ-on-a-chip technology. Organ-on-a-chip devices mimic the structure and function of human organs, enabling researchers to study the toxic effects of chemicals on specific organs in a more physiologically relevant context. These devices consist of microfluidic channels lined with human cells, creating a miniaturized version of the organ. Organ-on-a-chip models have been developed for various organs, including the liver, lung, kidney, and heart, allowing for the assessment of organspecific toxicity and the evaluation of drug metabolism and toxicity [2].

Advancements in genomics and epigenomics have also revolutionized toxicology. Genome-wide association studies (GWAS) and transcriptomics analyses have identified genetic variants and gene expression profiles associated with susceptibility to certain toxicants. These findings provide insights into the underlying mechanisms of toxicity and help identify individuals at higher risk. Epigenetic modifications, such as DNA methylation and histone modifications, have also been implicated in toxicological responses. Epigenomic studies can uncover epigenetic changes induced by toxicants, providing a deeper understanding of their long-term effects and potential transgenerational impacts [3].

Furthermore, the field of toxicogenomics integrates genomics, transcriptomics, proteomics, and metabolomics to comprehensively analyze the effects of toxicants on biological systems. Toxicogenomic approaches allow for the identification of gene expression signatures and metabolic pathways perturbed by toxicants, providing valuable information on the mode of action and potential biomarkers of toxicity. Additionally, machine learning algorithms can be applied to toxicogenomic data to develop predictive models for toxicity, aiding in the identification of new drug targets and the development of personalized medicine approaches [4].

Finally, the advent of systems toxicology has shifted the focus from studying individual toxicants to understanding the complexity of chemical mixtures and their combined effects on biological systems. Traditional toxicology often underestimated the synergistic or antagonistic interactions between chemicals. Systems toxicology incorporates a systems biology approach, integrating data from multiple levels of biological organization to unravel the network of interactions between chemicals and biological pathways. This holistic perspective provides a more comprehensive understanding of toxicity and enables the identification of key nodes and pathways involved in adverse outcomes [5].


In conclusion, novel approaches in clinical and experimental toxicology have transformed the field by unraveling the mechanisms of toxicity at multiple levels. The integration of high-throughput screening, organ-on-a-chip technology, genomics, epigenomics, toxicogenomics, and systems toxicology has led to more accurate risk assessment, the identification of new drug targets, and the development of personalized medicine approaches. These advancements hold great promise for improving human health by facilitating the development of safer chemicals and therapeutics while minimizing the use of animal models. However, further research and validation are necessary.


  1. Powell LG, Gillies S, Fernandes TF, et al., . Developing Integrated Approaches for Testing and Assessment (IATAs) in order to support nanomaterial safety. Nanotox. 2022; 16(4):484-99.
  2. Indexed at, Google Scholar, Cross Ref

  3. Menegola E, Veltman CH, Battistoni M, et al.,. An adverse outcome pathway on the disruption of retinoic acid metabolism leading to developmental craniofacial defects. Toxi. 2021;458:152843.
  4. Indexed at, Google Scholar, Cross Ref

  5. Zhao S, Zhang Q, Liu M, et al.,. Regulation of plant responses to salt stress. Int J Mol Sci.2021 ;22(9):4609.
  6. Indexed at, Google Scholar, Cross Ref

  7. Zhang L, Wu X, Yang R, et al., . Effects of berberine on the gastrointestinal microbiota. Front cell infect. 2021; 10:588517.
  8. Indexed at, Google Scholar, Cross Ref

  9. Böttger F, Vallés-Martí A, Cahn L, et al., . High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. J Exp Clin Cancer Res. 2021;40(1):1-44.
  10. Indexed at, Google Scholar, Cross Ref

Get the App